福元医药：子公司获得水杨酸苯酚贴膏药品补充申请批准通知书

Core Viewpoint - Fuyuan Pharmaceutical's subsidiary has received approval for the supplementary application of Salicylic Acid Phenol Plaster, enhancing the company's product line and market presence [1] Company Summary - Fuyuan Pharmaceutical's wholly-owned subsidiary, Fuyuan Pharmaceutical Co., Ltd., has been granted the "Drug Supplementary Application Approval Notice" for Salicylic Acid Phenol Plaster by the National Medical Products Administration [1] - The marketing authorization holder for this drug has been transferred from Xi'an Kanghua Pharmaceutical Co., Ltd. to Fuyuan Pharmaceutical Co., Ltd. [1] - The drug is primarily used for treating corns, and 16 other companies have also received marketing approvals for similar products [1] Market Summary - The estimated sales revenue for Salicylic Acid Phenol Plaster in China's three major terminal markets is approximately 68.92 million yuan in 2024 [1] - The approval allows Fuyuan Pharmaceutical to further diversify its product offerings, although future sales may be impacted by national policies and market conditions [1]